This study will be conducted primarily to determine the pharmacokinetics of copanlisib in
Chinese patients with relapsed iNHL.
The primary objective of the study is to determine the pharmacokinetics of copanlisib
administered on Day1, 8, and 15 of a 28-days cycle (3 weeks-on/1 week off dosing regimen) as
a 1 hour intravenous infusion to Chinese patients with relapsed iNHL.
The secondary objectives include the evaluation of safety, tolerability, and tumor response
of Chinese patients treated with Copanlisib.
Determine the pharmacokinetics of M-1 metabolite.